Skip to main content
Egetis Therapeutics logo

Egetis Therapeutics — Investor Relations & Filings

Ticker · EGTX ISIN · SE0003815604 LEI · 549300RZCKGWRUBPMY22 ST Manufacturing
Open in API
Filings indexed 284 across all filing types
Latest filing 2023-05-23 Regulatory Filings
Country SE Sweden
Listing ST EGTX

About Egetis Therapeutics

https://www.egetis.com/

Egetis Therapeutics is an innovative and integrated pharmaceutical company focused on developing and commercializing treatments for serious and rare diseases with significant unmet medical needs. The company's strategy centers on advancing drug candidates through late-stage clinical development to market approval. Its primary asset, Emcitate (tiratricol), is a first-in-class drug candidate in late-stage development for the treatment of Monocarboxylate Transporter 8 (MCT8) deficiency, a rare congenital disorder of thyroid hormone transport.

Recent filings

Filing Released Lang Actions
Egetis announces termination of discussions regarding a potential acquisition of the Company and provides a corporate update
Regulatory Filings Classification · 97% confidence The document is a press release titled "Egetis announces termination of discussions regarding a potential acquisition of the Company and provides a corporate update." It discusses the termination of M&A discussions, provides updates on regulatory submissions (MAA to EMA, NDA to FDA), clinical trial progress, and includes a concluding statement that references EU Market Abuse Regulation compliance and provides contact information. This content structure—a corporate announcement regarding strategic events, regulatory timelines, and business updates, often released via regulatory news services—does not fit neatly into the specific financial report categories (10-K, IR, ER, IP). Since it is a general corporate announcement that doesn't fit the specific definitions for M&A activity (TAR, which is for the proposal/bid itself), Director's Dealing (DIRS), or Capital Changes (CAP), the most appropriate fallback category for a general regulatory announcement of this nature is Regulatory Filings (RNS). The document length is substantial (6524 chars), so it is not an RPA.
2023-05-23 English
Egetis meddelar att diskussionerna om ett potentiellt förvärv av Bolaget har avslutats samt ger en bolagsuppdatering
M&A Activity Classification · 99% confidence The document is a press release dated May 23, 2023, announcing that discussions regarding a potential acquisition have concluded and providing a company update, specifically regarding the timeline for submitting a Marketing Authorization Application (MAA) for their drug Emcitate. It mentions regulatory compliance ("EU:s marknadsmissbruksförordning") and provides contact information and a link to the full document (PDF). This structure—a brief announcement about company developments, often including regulatory updates or strategic shifts, released via a news wire—is characteristic of a general regulatory announcement or press release. Since it is not a full Annual Report (10-K), a specific Earnings Release (ER), or a dedicated Investor Presentation (IP), and it is clearly a formal announcement of material information, the most appropriate classification is Regulatory Filings (RNS), which serves as the general category for such official, non-standardized announcements, especially when they relate to market-sensitive information like M&A discussions ending and regulatory timelines shifting. It is not a Report Publication Announcement (RPA) because it is the primary content itself, not just an announcement *about* a report being attached, although it does link to a PDF.
2023-05-23 Swedish
Bulletin from Egetis Therapeutics’ Annual General Meeting 2023
AGM Information Classification · 98% confidence The document is explicitly titled 'Bulletin from Egetis Therapeutics' Annual General Meeting 2023' and details the resolutions passed during the AGM held on April 27, 2023, including board elections, remuneration approvals, and authorization for share issuance. This content directly corresponds to the definition of AGM Information. Although it mentions that the complete minutes will be made available later, the document itself is a summary bulletin of the meeting's outcomes, making AGM-R the most appropriate classification over RPA or RNS.
2023-04-27 English
Kommuniké från Egetis Therapeutics årsstämma 2023
AGM Information Classification · 99% confidence The document is explicitly titled 'Kommuniké från Egetis Therapeutics årsstämma 2023' (Communiqué from Egetis Therapeutics Annual General Meeting 2023). It details decisions made during the meeting, such as the approval of financial statements, election of board members, determination of director fees, appointment of auditors, and approval of incentive programs. These contents are characteristic of materials presented or summarized following an Annual General Meeting (AGM). Therefore, the appropriate classification is AGM-R.
2023-04-27 Swedish
Earnings Release 2023
Earnings Release Classification · 99% confidence The document contains a detailed 'Finansiell översikt' (Financial overview) with comparative figures for Q1 2023, Q1 2022, and FY 2022, including revenue, net result, cash flow, and EPS. It also includes a 'VD har ordet' (CEO's word) section discussing financing activities (a directed new share issue) and extensive updates on clinical trial progress (Emcitate and Aladote) with specific regulatory milestones (EMA MAA submission planned for Q2 2023, US NDA submission planned for Q4 2023). The structure, content (financial tables, management commentary, pipeline updates), and reporting period focus strongly indicate this is a comprehensive report covering a period shorter than a full year, specifically the first quarter. This aligns perfectly with the definition of an Interim/Quarterly Report (IR). It is not a brief announcement (RPA/ER) because it contains detailed financial tables and extensive narrative analysis. Q2 2023
2023-04-26 Swedish
Interim / Quarterly Report 2023
Interim / Quarterly Report Classification · 100% confidence The document is a comprehensive financial report for Egetis Therapeutics covering the period of January-March 2023. It includes detailed financial tables (Net revenues, Result after tax, Cash flow, etc.), management commentary from the CEO, project updates, and operational highlights. Since it covers a period shorter than a full fiscal year and contains substantive financial data and analysis, it is classified as an Interim/Quarterly Report. Q2 2023
2023-04-26 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.